Cantor Fitzgerald Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Cantor Fitzgerald has maintained its Neutral rating for Regeneron Pharmaceuticals (NASDAQ:REGN) but raised its price target from $850.00 to $925.00. Despite this, REGN's current share price of $938.59 indicates a potential downside according to the new target. Regeneron is known for its products in various medical fields, including eye disease and cancer, and has partnerships for developing new technologies.

February 06, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cantor Fitzgerald maintains Neutral on REGN, raises target to $925. Current price $938.59 suggests downside. REGN develops treatments for various diseases and has key partnerships.
The adjustment of the price target by Cantor Fitzgerald, despite being an increase, still suggests a potential downside from the current trading price of REGN. This could lead to short-term negative sentiment among investors, especially considering the Neutral rating was maintained. The company's strong portfolio and partnerships indicate long-term value, but the immediate market reaction might lean towards the analyst's implied valuation.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100